<DOC>
	<DOCNO>NCT02875314</DOCNO>
	<brief_summary>This prospective randomized clinical trial , determine whether dose-intensive tandem Consolidation , randomize comparison single cycle Consolidation , provide event-free survival ( EFS ) overall survival ( OS ) . The study population high-risk patient ( non-Wnt non-Shh sub-groups ) medulloblastoma , patient central nervous system ( CNS ) embryonal tumor complete `` Head Start 4 '' Induction . This study determine whether additional labor intensity ( duration hospitalization short-term long-term morbidity ) associate tandem treatment justified improvement outcome . It expect tandem ( 3 cycle ) Consolidation regimen produce superior outcome compare single cycle Consolidation , give substantially high dose intensity tandem regimen , without significant addition either short-term long-term morbidity .</brief_summary>
	<brief_title>HeadStart4 : Newly Diagnosed Children ( &lt; 10 y/o ) With Medulloblastoma Other CNS Embryonal Tumors</brief_title>
	<detailed_description>Due inferior response event-free survival data Regimens D D2 `` Head Start III '' child supratentorial embryonal tumor , comparison publish data `` Head Start II '' Regimen A2 metastatic patient , patient receive `` Head Start II '' Induction Regimen A2 , `` Head Start 4 '' , either three five cycle , depend upon whether achieve complete remission end Induction cycle # 3 . They undergo randomization either single cycle three tandem cycle Consolidation marrow-ablative chemotherapy AuHPCR . Because unsatisfactory event-free survival young child non-desmoplastic/extensive nodular medulloblastoma ( predominantly non-Shh non-Wnt medulloblastoma subgroup ) Regimens D D2 `` Head Start III '' , patient receive `` Head Start II '' Induction Regimen A2 `` '' Head Start 4 '' '' , either three five cycle , depend upon whether achieve complete remission end Induction cycle # 3 . They undergo randomization either single cycle three tandem cycle Consolidation marrow-ablative chemotherapy AuHPCR . Because excellent event-free overall survival young child good risk medullo-blastoma ( Shh Wnt subgroup ) treat up-front `` Head Start '' chemotherapy strategy , patient undergo risk-tailored reduction duration Induction therapy five cycle three cycle `` Head Start II '' Induction Regimen A2 `` Head Start 4 '' patient achieve complete response 3 cycle , follow , provide also without evidence residual tumor follow recovery Induction cycle # 3 . They NOT undergo randomization , follow single cycle Consolidation marrow-ablative chemotherapy `` Head Start '' study .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients 10 year age time definitive confirmatory eligible histologic cytologic diagnosis eligible CNS tumor ( brain spinal cord ) Patients may receive irradiation chemotherapy ( except corticosteroid ) Have histologically prove diagnosis medulloblastoma CNS embryonal tumor brain spinal cord Medulloblastoma Posterior fossa classic , desmoplastic extensive nodular anaplastic/large cell medulloblastoma appropriate sufficient tumor material ( FFPE snap freeze ) propose assay : stage , age le 6 year diagnosis Posterior fossa classic anaplastic/large cell medulloblastoma sufficient tumor material ( FFPE snap freeze ) propose assay : clinically highstage ( neuraxis extraneural dissemination , M14 ) , age great 6 year less 10 year diagnosis Posterior fossa medulloblastoma , 6 year age diagnosis , eligible evidence neuraxis extraneural dissemination . Patients 6 year age lowstage ( standardrisk , M0 ) medulloblastoma NOT eligible study , irrespective molecular subgroup extend local resection CNS Embryonal Tumors : Pineoblastoma , CNS neuroblastoma , CNS ganglioneuroblastoma , embryonal tumor multilayered rosette ( ETMR , include embryonal tumor abundant neuropil true rosette ( ETANTR ) , ependymoblastoma ETMR otherwise specify ) , medulloepithelioma , CNS embryonal tumor rhabdoid feature ( INI1 intact ) CNS embryonal tumor , otherwise specify . Must commence Induction chemotherapy within 28 day recent definitive surgical procedure within 21 day recent neuroimaging study ( MRI brain , perform without gadolinium contrast , MRI total spine , perform gadolinium contrast ) lumbar CSF cytological examination Patients must adequate organ function time registration : Liver : bilirubin le 1.5 mg/dL ( except patient Gilbert 's Syndrome indirect hyperbilirubinemia ) transaminases [ SGPT ALT , SGOT AST ] le 2.5 ( two half ) time upper limit institutional normal . Renal : Creatinine clearance and/or glomerular filtration rate ( GFR ) great equal 60 mL/min/1.73m² within 21 day protocol therapy . Bone Marrow Function : 1 . Peripheral absolute phagocyte count ( APC ) &gt; 1000/ µL . APC = number band neutrophil + segment neutrophil + metamyelocytes + monocyte + eosinophils Please note , institution report differential percentage , APC = [ percentage band neutrophil + segment neutrophils+ metamyelocytes+monocytes+eosinophils ] x total white cell count . 2 . Platelet Count &gt; 100,000/µL ( transfusion independent ) 3 . Hemoglobin &gt; 8 gm/dL ( may receive RBC transfusion ) . Patients older 10 year age time diagnosis Following diagnosis eligible study enrollment : CNS atypical teratoid/rhabdoid tumor ( AT/RT ) ; ependymomas include anaplastic ependymomas brain spinal cord ; choroid plexus carcinoma ; highgrade glial glioneuronal tumor ; primary CNS germ cell tumor ; primary CNS sarcoma ; primary metastatic CNS lymphoma solid leukemic lesion ( i.e. , chloromas , granulocytic sarcoma ) . Patients unbiopsied diffuse intrinsic pontine tumor NOT eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>